Welcome to our dedicated page for Eliem Therapeutics news (Ticker: ELYM), a resource for investors and traders seeking the latest updates and insights on Eliem Therapeutics stock.
Eliem Therapeutics, Inc. (NASDAQ: ELYM) is a clinical-stage biotechnology company focused on developing innovative therapies for neuronal excitability disorders, including chronic pain, depression, epilepsy, and anxiety. Headquartered in Seattle with significant R&D operations in Cambridge, UK, Eliem is dedicated to improving patients' quality of life by delivering potentially best-in-class drug candidates. The company's flagship product candidate, ETX-155, is in development for major depressive disorder (MDD) and focal onset seizures (FOS).
Founded on a mission to empower patients to live on their own terms, Eliem Therapeutics leverages its extensive experience and passion in the biotechnology field to address unmet medical needs. The company is motivated by the promise of helping patients lead happier, more fulfilling lives.
Recent achievements include the evaluation of strategic alternatives that may involve acquisitions, mergers, business combinations, or other transactions. As of June 30, 2023, Eliem reported approximately $102.6 million in cash, cash equivalents, and investments in marketable securities, underscoring a strong financial position to support ongoing and future projects.
Eliem's research and development primarily focus on conditions that cause significant suffering to millions of people every day. By developing novel therapies, the company aims to offer new hope to those affected by neuronal excitability disorders. Eliem's commitment extends to staying transparent with its community through regular updates and adherence to community guidelines.
For more information or to engage with the community, please visit the company's community engagement page.
Eliem Therapeutics (Nasdaq: ELYM) provided a business update and reported financial results for Q1 2022, highlighting ongoing developments in their pipeline aimed at neuronal excitability disorders, including chronic pain and epilepsy.
Despite challenges with ETX-810 in diabetic peripheral neuropathic pain, they anticipate topline data for lumbosacral radicular pain by Q3 2022. Their cash position stands at $149.9 million, projected to fund operations through at least 2023, while R&D expenses increased to $8.3 million.
Eliem Therapeutics (Nasdaq: ELYM) announced that its Phase 2a trial of ETX-810 for diabetic peripheral neuropathic pain (DPNP) did not meet the primary endpoint, showing no significant difference from placebo. Despite prior positive data on ETX-810's mechanism, the trial's results were disappointing, indicating no further development in DPNP. Meanwhile, the Phase 2a trial for lumbosacral radicular pain (LSRP) is fully enrolled, with topline data expected in Q3 2022. Additionally, ETX-155’s Phase 2a trials for depression are delayed due to inconclusive Phase 1b results.
Eliem Therapeutics, Inc. (Nasdaq: ELYM) has appointed Susan Franks as Senior Vice President and Head of Regulatory Affairs, enhancing its executive team. With over 30 years of global regulatory experience, particularly in pain and CNS drug development, Franks is expected to lead regulatory efforts for Eliem’s pipeline. The company is advancing clinical programs for ETX-810 and ETX-155, with upcoming Phase 2 studies. Franks' previous roles include regulatory leadership at Braeburn Inc. and Teva Pharmaceuticals, contributing to significant drug registrations.
Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology firm, focuses on therapies for neuronal excitability disorders, including chronic pain and epilepsy. On March 29, 2022, Bob Azelby, president and CEO, will present at Stifel’s 2022 CNS Days, starting at 9:30 AM ET. A live webcast will be available on their website, with a replay for 30 days post-event. Eliem aims to develop differentiated product candidates to enhance patient quality of life by restoring neuronal balance in various disorders.
Eliem Therapeutics (Nasdaq: ELYM) announced the completion of dosing in its Phase 2a trial of ETX-810 for diabetic peripheral neuropathic pain, with topline data expected in 1H 2022. The company also submitted an IND application for ETX-155 targeting depression and epilepsy. For the year ended December 31, 2021, Eliem reported a net loss of $47.5 million and R&D expenses of $23.3 million. Cash reserves were $161.4 million, sufficient to support operations through late 2023. The ongoing studies aim to address significant unmet needs in chronic pain and psychiatric disorders.
Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company, announced that Bob Azelby, its President and CEO, will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 3:00 PM ET. The presentation will focus on developing novel therapies for neuronal excitability disorders, including chronic pain, psychiatry, and epilepsy. A live webcast will be available on their website, with a replay accessible for 30 days post-conference. Eliem aims to enhance patient quality of life through innovative therapeutic approaches.
Eliem Therapeutics, Inc. (Nasdaq: ELYM) has announced a virtual investor event on February 16, 2022, at 10:30 a.m. ET. The event will feature presentations from Eliem's CEO Bob Azelby and Chief Scientific Officer Valerie Morisset, alongside expert insights from Dr. John D. Markman and Dr. Stuart Bevan. Key topics will include the unmet needs in chronic pain treatment, supporting data for the mechanism of ETX-810, and its clinical program. Interested parties can register for the event via the link provided.
Eliem Therapeutics, Inc. (Nasdaq: ELYM) has fully enrolled its Phase 2a trial of ETX-810 for chronic diabetic peripheral neuropathic pain. The company expects topline data in the first half of 2022. Additionally, it plans to submit an IND application for ETX-155, targeting major depressive disorder and perimenopausal depression, in Q1 2022. The Phase 1b trial for ETX-155 in epilepsy is underway. As of December 31, 2021, Eliem holds approximately $160 million in cash, expected to fund operations through late 2023.
Eliem Therapeutics (Nasdaq: ELYM) reported substantial advancements in their clinical programs as of November 8, 2021. The company successfully screened its first patient in a proof-of-concept trial for ETX-155, targeting epilepsy, with Phase 2a trials for major depressive disorder (MDD) and perimenopausal depression (PMD) set to commence in early 2022. Additionally, the ongoing Phase 2a trials for ETX-810 are on track for topline data in the first half of 2022. Despite a net loss of $9.6 million for Q3 2021, cash reserves of $169.6 million are expected to support operations through late 2023.
Eliem Therapeutics, a biotechnology company focused on therapies for neuronal excitability disorders, will participate in four upcoming investor conferences. Key events include the Virtual Guggenheim Neuro/Immunology Conference on November 15-16, 2021, and the Stifel 2021 Virtual Healthcare Conference with a fireside chat on November 17 at 2:00 p.m. ET. The 33rd Annual Piper Sandler Virtual Healthcare Conference will run from November 30 to December 2, featuring a pre-recorded chat available starting November 22. The Evercore ISI 4th Annual HealthCONx Conference will also include a fireside chat on November 30 at 1:00 p.m. ET.
FAQ
What is the current stock price of Eliem Therapeutics (ELYM)?
What is the market cap of Eliem Therapeutics (ELYM)?
What does Eliem Therapeutics, Inc. do?
Where is Eliem Therapeutics located?
What is Eliem Therapeutics' main product candidate?
What recent financial updates has Eliem Therapeutics provided?
What strategic alternatives is Eliem Therapeutics exploring?
What motivates the Eliem Therapeutics team?
Is Eliem Therapeutics a publicly traded company?
What disorders are targeted by Eliem's therapies?
How can I learn more about Eliem Therapeutics' community guidelines?
Who can I contact for investor-related questions?
